Pleasanton, CA, November 27, 2017 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the HyperCap Target Enrichment Portfolio, a streamlined and fully integrated NGS sample preparation. HyperCap integrates KAPA DNA Library Prep with SeqCap EZ target enrichment portfolio, and is a further expansion of the HyperCap v1.0 workflow.
As part of the HyperCap Target Enrichment Portfolio launch, Roche is also introducing Universal Blocking Oligos, which enhance the performance of capture experiments through the prevention of cross-hybridization between adapter sequences, providing customers with a more convenient way to obtain all necessary workflow reagents from a single vendor.
“The introduction of the HyperCap Kits further exemplifies Roche’s commitment to creating a simplified workflow that addresses NGS researchers sample prep needs worldwide,” said Neil Gunn, Head of Roche Sequencing Solutions.
HyperCap Target Enrichment Portfolio
Established in 2016 as a standalone workflow more streamlined than its predecessor, SeqCap EZ v5.1, HyperCap Kits are a fully integrated product comprised of Roche’s library preparation and target enrichment portfolios, providing a complete and streamlined NGS sample prep solution from Roche. HyperCap Kits are for research use only and not for use in diagnostic procedures.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit: www.roche.com.
All trademarks used or mentioned in this release are protected by law.